The Future of ER+/HER2- mBC Treatment
Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
Key Efficacy Data from Sub-Group Analyses of Patients from the EMERALD Trial
Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes
Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial.
Biomarker Testing in Patients With ER+/HER2- mBC
Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.
An Introduction to ER+/HER2- mBC and Current Treatment Options
Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.
Antibody Drug Conjugate Sacituzumab Govitecan Shows Efficacy in TNBC
Aditya Bardia, MD, MPH, discusses the efficacy of sacituzumab govitecan in patients with triple-negative breast cancer.
Dual Targeting of the HER2 Receptor
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
Recent Advancements in the Field of Breast Cancer
Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.
The Snapshot Tumor Genotyping Assay for Breast Cancer
Aditya Bardia, MD, MPH, Attending Physician, Massachusetts General Hospital, Harvard Medical School, gives an overview of the Snapshot assay for breast cancer.